[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lumbar-fusion-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lumbar-fusion-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100630527","intravenous-lidocaine-infusion-in-lumbar-fusion-surgery-100630527",false,"NCT07488832","Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Opioid Consumption and Recovery After Lumbar Fusion Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Scheduled for elective lumbar fusion surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* ASA physical status ≥III\n* Body mass index \\>35 kg\u002Fm²\n* Known allergy or hypersensitivity to lidocaine or study medications\n* Severe cardiac, hepatic, or renal disease\n* Pregnancy\n* Neurological disorders affecting pain assessment\n* Chronic opioid use\n* Use of opioids or antiemetic drugs before surgery\n* Inability to cooperate with postoperative assessments","ALL","18 Years","65 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.\n\nThis randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.\n\nThe primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.",[27],"Lumbar Fusion Surgery",[29,30,31,32,33],"Lumbar fusion surgery","Intravenous lidocaine infusion","Postoperative pain","Opioid consumption","Postoperative recovery","RECRUITING","2026-04-02",{"date":37,"type":38},"2026-04-08","ACTUAL",{"date":40,"type":38},"2026-04-01",{"date":42,"type":21},"2027-01-01",{"name":44,"class":45},"Ankara City Hospital Bilkent","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100573581","phase-2-io-vancomycin-spine-100573581","NCT06748144","IO Vancomycin Spine","Intraosseous vs. Intravenous Vancomycin Administration in Spine Surgery","Inclusion Criteria:\n\n* Patient is undergoing open posterior instrumented spinal fusion (PSIF) or transforaminal lumbar interbody fusion (TLIF)\n* Patient is able to give informed consent to participate on the study. LAR consents will not be utilized for this study\n* Age Range \\>18\n\nExclusion Criteria:\n\n* Previous spine surgery if surgeon deems it will affect the study\n* BMI \\> 40\n* Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).\n* Inability to administer the IO infusion\n* Refusal to participate\n* Diabetes as defined as uncontrolled A1C \\> 7.5 and eGFR \\\u003C59\n* Immunocompromised or immunosuppressed patients (HIV, Hep C, ESRD, dialysis, transplant, chemo\u002Fradiation treatment in last 6 months, medications)\n* No vulnerable populations",{"count":55,"type":21},30,[57,58],"PHASE2","PHASE3","The goal of this research is to learn if injecting the antibiotic vancomycin directly into the bone marrow (intraosseous) or IO) during a lumbar (spinal) fusion surgery, is as effective or better than the standard method of giving it vancomycin through a vein (intravenous) or IV) during lumbar fusion surgery.",[27],"NOT_YET_RECRUITING","2026-03-24",{"date":64,"type":38},"2026-03-25",{"date":66,"type":21},"2026-05",{"date":68,"type":21},"2030-04",{"name":70,"class":45},"The Methodist Hospital Research Institute",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100596041","evaluation-of-the-efficacy-and-safety-of-absorbable-vs-traditional-bone-wax-for-facet-fusion-after-lumbar-fusion-surgery-100596041","NCT07040293","Evaluation of the Efficacy and Safety of Absorbable vs Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery","Evaluation of the Efficacy and Safety of Absorbable Bone Wax and Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery: A Multicenter, Randomized, Open-label, Superiority Clinical Trial","Inclusion Criteria:\n\n* Participants must be aged between 18 and 75 years, with no restrictions on gender.\n* Participants with conditions such as single-segment lumbar intervertebral disc protrusion, lumbar spondylolisthesis, and lumbar spinal stenosis who are scheduled to undergo posterior decompression, intervertebral fusion, and internal fixation surgery.\n* Participants must be able to comprehend the objectives of the study, willingly participate, and provide informed consent by signing the consent form.\n\nExclusion Criteria:\n\n* Individuals with a hemorrhagic predisposition or coagulation disorders, indicated by a prothrombin time (PT) of 18 seconds or greater, and those with a history of prolonged anticoagulant use.\n* Individuals presenting with lumbar spine infections or fractures.\n* Individuals with known allergies to materials such as polyethylene glycol, sodium carboxymethyl cellulose, and bone wax (including beeswax, paraffin, and isopropyl palmitate).\n* Individuals whose conditions are critical, making it challenging to accurately assess the efficacy and safety of the equipment.\n* Individuals deemed by researchers to have poor compliance, rendering them unable to fulfill the study requirements.\n* Women who are currently pregnant, intend to become pregnant within the past year, or are breastfeeding.\n* Individuals who have participated in other clinical trials within the preceding 30 days to prevent cross-interference.\n* Individuals with significant complications or comorbidities, such as severe cardiovascular, hepatic, renal, or other chronic conditions that could influence surgical risks and research outcomes.\n* Individuals identified by researchers as having a life expectancy of less than six months.\n* Individuals with severe osteoporosis, defined as a bone mineral density T-score of ≤-2.5 accompanied by fragility fractures.\n* Any other individuals deemed unsuitable for participation in this clinical trial by the researchers.","75 Years",{"count":80,"type":21},330,[24],"Hemorrhage on the surface of cancellous bone presents a significant challenge in orthopedic surgery. Traditional bone wax, commonly utilized for hemostasis in bone wounds, is non-absorbable and associated with various complications, including pseudarthrosis, paralysis, venous sinus thrombosis, chronic inflammation, allergic reactions, and infections, thereby limiting its clinical utility. In contrast, absorbable bone wax, primarily composed of medical-grade water-soluble polymer materials, exhibits excellent biocompatibility. It is fully absorbed, excreted, or eliminated by the body without leaving toxic residues. This study employs a rigorous efficacy design to select an appropriate patient cohort for lumbar fusion surgery, based on specific inclusion and exclusion criteria. Participants are randomly assigned to either an experimental group receiving absorbable bone wax or a control group receiving traditional bone wax, facilitating a randomized, open-label, parallel-controlled clinical trial. This study aims to evaluate the comparative effects of absorbable bone wax versus traditional bone wax on the rate of bone fusion following hemostasis of bone wounds. The objective is to furnish robust evidence-based insights into the application of absorbable bone wax for bone wounds necessitating fusion, thereby establishing a safe, effective, and broadly applicable technique for bone wound hemostasis in clinical practice.",[27,84],"Fusion of Joint",[86,87,88,89],"absorbable bone wax","traditional bone wax","facet fusion after lumbar fusion surgery","hemostasis","2025-06-26",{"date":92,"type":38},"2025-06-27",{"date":94,"type":21},"2025-07-01",{"date":96,"type":21},"2028-06-30",{"name":98,"class":45},"Shanghai Changzheng Hospital"]